

(19)

Europäisches Patentamt  
European Patent Office  
Office européen des brevets



(11)

**EP 1 281 398 A1**

(12)

**EUROPEAN PATENT APPLICATION**  
published in accordance with Art. 158(3) EPC

(43) Date of publication:

**05.02.2003 Bulletin 2003/06**

(21) Application number: **01929996.5**

(22) Date of filing: **09.05.2001**

(51) Int Cl.7: **A61K 31/05, A61K 31/122, A61K 9/06, A61K 9/107, A61K 7/00, A61K 7/40, A61P 37/08, A61P 17/00, A61P 17/02, A61P 17/04, A61P 17/06, A61P 17/08**

(86) International application number:  
**PCT/JP01/03863**

(87) International publication number:  
**WO 01/085156 (15.11.2001 Gazette 2001/46)**

(84) Designated Contracting States:

**AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE TR**

(30) Priority: **09.05.2000 JP 2000135568**

(71) Applicant: **KANEKA CORPORATION**  
**Osaka-shi, Osaka 530-8288 (JP)**

(72) Inventors:

- **FUJII, Kenji**  
**Kobe-shi, Hyogo 651-1202 (JP)**


- **KAWABE, Taizo**  
**Takasago-shi, Hyogo 676-0082 (JP)**
- **HOSOE, Kazunori**  
**Takasago-shi, Hyogo 676-0025 (JP)**
- **HIDAKA, Takayoshi**  
**Kobe-shi, Hyogo 655-0006 (JP)**

(74) Representative:


**Gille Hrabal Struck Neldlein Prop Roos**  
**Patentanwälte**  
**Brucknerstrasse 20**  
**40593 Düsseldorf (DE)**

(54) **DERMAL COMPOSITIONS CONTAINING COENZYME Q AS THE ACTIVE INGREDIENT**

(57) The present invention provides a composition for dermal application which comprises, as an active ingredient, an oxidized coenzyme Q represented by the formula (1):



in which n represents an integer of 1 to 12,  
and/or a reduced coenzyme Q represented by the formula (2) :



in which n represents an integer of 1 to 12,  
the total content of the oxidized coenzyme Q and reduced coenzyme Q being 0.01 to 99% by weight relative to the whole amount of the composition.

The present invention also provides a therapeutic composition for skin diseases, a cosmetic composition, a skin health care composition and a bath salt composition, each comprising the above composition for dermal application.

The present invention is further provides a method for the treatment of skin diseases

which comprises applying, to a patient suffering from a skin disease, the above-mentioned therapeutic composition for skin diseases, or

a method for the treatment of skin diseases

which comprises applying, to a patient suffering from a skin disease, the above therapeutic agent for skin diseases other than the oxidized coenzyme Q represented by the formula (1) and other than the reduced coenzyme Q represented by the formula (2) in parallel with a therapeutic composition for skin diseases.

**Description**

## TECHNICAL FIELD

5   **[0001]** The present invention relates to a composition for dermal application which contains a coenzyme Q as an active ingredient, in particular to a composition for the treatment of skin diseases, a cosmetic composition, a skin health care composition and a bath salt composition, and to a method for the treatment of skin diseases using that composition for dermal application.

## 10   BACKGROUND ART

**[0002]** Coenzymes Q are physiologically essential factors distributed widely in living organisms, from bacteria to mammals, and occur as constituents of the mitochondrial electron transport system in cells of the living organism. Coenzymes Q function as carrier components in the electron transport system by repeating oxidation and reduction in *in vivo*, and reduced coenzymes Q are also known as antioxidants. In many animals inclusive of human beings, or in fish and birds, coenzyme Q<sub>10</sub>, which is a coenzyme Q whose side chain comprises 10 repetitions of a unit, is predominant. Further, it is known that about 40 to 90% of this coenzyme Q<sub>10</sub> occurs in reduced form in living organisms.

**[0003]** As for the practical uses of coenzymes Q, oxidized coenzyme Q<sub>10</sub>, for instance, has been used as a drug for congestive heart failure and, in other fields than the pharmaceutical field, it has been used widely as a nutrient or nutritional supplement, like vitamins. However, reduced coenzyme Q<sub>10</sub> has not yet been put to practical use.

**[0004]** In Japanese Kohyo Publication Hei-09-501925, there is disclosed a dermal preparation containing oxidized coenzyme Q<sub>10</sub> (ubiquinone) or reduced coenzyme Q<sub>10</sub> (ubiquinol) as a coenzyme Q<sub>10</sub>. In this document, however, it is disclosed only as one of a large number of examples of the active ingredient. As regards ubiquinol, in particular, no example is given for the actual use thereof. It is described that such coenzyme Q<sub>10</sub>-containing dermal preparations are effective against atopic dermatitis. However, the name of that disease, too, appears only as an example of a large number of skin diseases. There is no relevant example, hence the actual effect is unknown.

**[0005]** In Japanese Kokai Publication Hei-10-109933, the inventors of the present invention disclosed that the combined use of reduced coenzyme Q<sub>10</sub> and oxidized coenzyme Q<sub>10</sub> results in an improvement in oral absorbability as compared with the single use of oxidized coenzyme Q<sub>10</sub>. However, the effect of reduced coenzymes Q on absorbability upon administration via other routes than the oral or its efficacy in atopic dermatitis was quite unknown.

**[0006]** It is a problem that skin diseases exert great influences on the life of patients not only physically but also mentally. In particular, the number of patients suffering from the intractable skin disease atopic dermatitis, among others, is tremendous and, further, the number of adult patients with atopic dermatitis has been increasing in recent years, causing serious problems in their leading a social life.

**[0007]** Steroids are generally known as therapeutic agents for atopic dermatitis. However, their use is restricted in not a few instances because of their significant side effects and the possibility of their causing the rebound phenomenon. Therefore, they are not sufficiently effective agents to bring about complete recovery from atopic dermatitis. Furthermore, in cases where steroids are ineffective, there are, in fact, no therapeutic drugs available. It is also a social problem that there are victims of folk medicine.

**[0008]** Tacrolimus, which is an immunosuppressive, has recently been approved as a therapeutic agent for atopic dermatitis. However, its use in children has not yet been approved because of a strong fear of its producing side effects; thus, it cannot be said to be a safe agent.

**[0009]** Under such circumstances, the advent of a therapeutic agent that can be used safely against atopic dermatitis is earnestly demanded.

45

## SUMMARY OF THE INVENTION

**[0010]** It is an object of the present invention to provide a composition for dermal application which contains coenzyme Q, in particular coenzyme Q<sub>10</sub>, as an active ingredient, and thus provide a safe and highly effective therapeutic agent for skin diseases, in particular atopic dermatitis.

**[0011]** As a result of investigations made by the present inventors to solve the problems mentioned above, it was found that oxidized coenzyme Q<sub>10</sub> can produce an excellent therapeutic effect on atopic dermatitis. Surprisingly, it was also found that when oxidized coenzyme Q<sub>10</sub> is used in combination with an existing drug such as a steroid or tacrolimus, a synergistic effect, which is higher as compared with the single use of such an existing drug, can be obtained.


**[0012]** Further, the inventors of the present invention prepared a dermal preparation containing reduced coenzyme Q<sub>10</sub> and carried out a percutaneous absorption test, whereupon it was found that when a composition containing a certain proportion of reduced coenzyme Q<sub>10</sub> as coenzyme Q<sub>10</sub> is applied to the skin, a higher level of percutaneous absorption can be attained as compared with a composition containing oxidized coenzyme Q<sub>10</sub> alone and the amount

of coenzyme Q<sub>10</sub> in the skin can be much increased. Furthermore, it was surprisingly found that the content of reduced coenzyme Q<sub>10</sub>, which is the active principle showing antioxidant activity, in skin can be markedly increased by applying a composition containing reduced coenzyme Q<sub>10</sub> as compared with the application of oxidized coenzyme Q<sub>10</sub> alone. Heretofore, it has been considered that oxidized coenzyme Q<sub>10</sub>, when administered, is converted to the reduced form in vivo and thus can show antioxidant activity. However, our studies revealed that the reduction of oxidized coenzyme Q<sub>10</sub> in skin proceeds only very slowly and, therefore, the reduced form level is far inferior to that attainable by application of a composition containing reduced coenzyme Q<sub>10</sub>. By increasing the content in skin of reduced coenzyme Q<sub>10</sub>, which shows strong antioxidant activity, it becomes possible to expect higher levels of skin care activity as compared with the application of oxidized coenzyme Q<sub>10</sub> alone.


**[0013]** Further, the inventor of the present invention evaluated an ointment containing reduced coenzyme Q<sub>10</sub> for efficacy in the treatment of atopic dermatitis. As a result, it was found that a reduced coenzyme Q<sub>10</sub>-containing ointment is by itself highly effective and comparable in therapeutic effect to prednisolone. It was also found that when a reduced coenzyme Q<sub>10</sub>-containing ointment is used in combination with a steroid or tacrolimus, a more powerful therapeutic effect can be produced.

**[0014]** Furthermore, the inventor of the present invention found that such dermal preparation containing coenzyme Q<sub>10</sub> as main active ingredient has a skin restoration promoting activity. This suggests that coenzyme Q<sub>10</sub> be effective also against skin diseases, typically decubitus.

**[0015]** Thus, the present invention provides a composition for dermal application which comprises, as an active ingredient, an oxidized coenzyme Q represented by the formula (1):



wherein n represents an integer of 1 to 12, and/or a reduced coenzyme Q represented by the formula (2):



wherein n represents an integer of 1 to 12, the total content of the oxidized coenzyme Q and reduced coenzyme Q being 0.01 to 99% by weight relative to the whole amount of the composition.

**[0016]** The present invention also relates to a therapeutic composition for skin diseases, a cosmetic composition, a skin health care composition and a bath salt composition, each comprising the above composition for dermal application.

**[0017]** The present invention is further concerned with a method for the treatment of skin diseases which comprises applying, to a patient suffering from a skin disease, the above-mentioned therapeutic composition for skin diseases, or a method for the treatment of skin diseases

which comprises applying, to a patient suffering from a skin disease, the a therapeutic agent for skin diseases other than the oxidized coenzyme Q represented by the formula (1) and other than the reduced coenzyme Q represented by the formula (2) in parallel with above-mentioned therapeutic composition for skin diseases.

**[0018]** In the following, the present invention is described in detail.

#### DETAILED DISCLOSURE OF THE INVENTION.

**[0019]** The compounds represented by the above formula (1) are oxidized coenzymes Q, while the compounds represented by the above formula (2) are reduced coenzymes Q.

**[0020]** The method of obtaining oxidized coenzymes Q and reduced coenzymes Q is not particularly restricted but the coenzymes Q can be obtained in the conventional manner, for example by synthesis, fermentation, or extraction from natural sources. Or, also employable is a method comprising, for example, subjecting the product obtained in the above manner to chromatography and concentrating the oxidized coenzyme Q fraction or reduced coenzyme Q fraction in an eluate. The oxidized form of coenzyme Q can be obtained by a method known in the art. The reduced form of coenzyme Q may be obtained by adding a conventional reducing agent, such as sodium borohydride or sodium dithionite (sodium hydrosulfite), as necessary, to the above coenzyme Q and reducing the oxidized form of coenzyme Q contained in the above coenzyme Q to the reduced form of coenzyme Q in a conventional manner, followed by concentration by chromatography. It is also possible to obtain the reduced form of coenzyme Q by treating an existing highly pure coenzyme Q with such as a reducing agent as mentioned above.

**[0021]** The method of obtaining the composition of the present invention is not particularly restricted but the composition can be obtained, for example, by dissolving the reduced form of coenzyme Q obtained in the above manner and the oxidized form of coenzyme Q, which is commercially available or obtained by a method known in the art, either in admixture or individually, in an appropriate base. Alternatively, the mixture of reduced coenzyme Q and oxidized coenzyme Q as obtained in the above-mentioned process for coenzyme Q production may be dissolved as such in a base. The base may be selected according to need from among those conventionally used in pharmaceutical preparations, cosmetics and the like within the limits within which the effects of the present invention will not be lessened.

**[0022]** In the composition of the present invention, the total proportion of the oxidized coenzyme Q and reduced coenzyme Q relative to the whole amount of the composition (proportion of the oxidized coenzyme Q relative to the whole composition when the oxidized coenzyme Q alone is contained therein, or proportion of the reduced coenzyme Q relative to the whole composition when the reduced coenzyme Q alone is contained therein) is 0.01 to 99% by weight, preferably 0.1 to 95% by weight, more preferably 0.5 to 50% by weight, still more preferably 1 to 30% by weight.

**[0023]** From the percutaneous absorbability viewpoint, the proportion of the reduced coenzyme Q relative to the total amount of the oxidized coenzyme Q and reduced coenzyme Q is preferably not less than 20% by weight, more preferably not less than 40% by weight. However, a reduced coenzyme Q-free composition containing only the oxidized coenzyme Q can also be preferably used. Further, the proportion of the reduced coenzyme Q relative to the total amount of the oxidized coenzyme Q and reduced coenzyme Q is preferably not more than 95% by weight.

**[0024]** The oxidized coenzyme Q and reduced coenzyme Q which can be used in the practice of the present invention have a side chain in which, as shown by the above formulas (1) and (2), the number (n in each formula) of repetitions of the repeating unit is 1 to 12. Among them, those in which the number of repetitions of the repeating unit is 10, namely oxidized coenzyme Q<sub>10</sub> and reduced coenzyme Q<sub>10</sub>, are particularly preferred.

**[0025]** The above composition for dermal application, therapeutic composition for skin diseases, cosmetic composition, skin health care composition and bath salt composition may be intended for application to humans or for application to pets, domestic animals and/or birds, in particular dogs and/or cats.

**[0026]** The dosage form of the dermal composition of the present invention is not particularly restricted but includes, among others, cream-like, paste-like, jelly-like, gel-like, emulsion-like or liquid dosage forms prepared by dissolving or dispersing together the above agent(s) in appropriate bases (ointments, liniments, lotions, sprays, etc.), dosage forms prepared by spreading a solution or dispersion of the above agent(s) in a base onto supporting members (poultices etc.), and dosage forms prepared by spreading a solution or dispersion of the above agent(s) in a pressure sensitive adhesive composition onto supporting members (plasters, tapes, etc.).

**[0027]** The dermal composition of the present invention can be used as a therapeutic composition for skin diseases. The skin diseases which can be treated with the composition include, but are not limited to, atopic dermatitis, decubitus, wounds, burns, psoriasis, eruptions, contact dermatitis, seborrheic dermatitis, lichen simplex chronicus Vidal, nummular eczema, housewives' eczema, solar dermatitis, pruritus cutaneus, prurigo Devergie, drug eruption, lichen planus, pityriasis rubra pilaris, pityriasis rosea Gilbert, erythema, erythrodermia, wounds, athlete's foot, and skin ulcer, among others.

**[0028]** In using the dermal composition of the present invention as a therapeutic composition for skin diseases, the composition may further contain a substance showing antioxidant activity, for example superoxide dismutase, catalase, glutathione peroxidase, vitamin E, vitamin C, glutathione, glutathione reductase, a polyvalent unsaturated fatty acid or

the like. It may also contain a skin activating ingredient, for example collagen, hyaluronic acid, mutin, a ceramide, squalene, squalane or the like, or a percutaneous absorption promoter.

[0029] It may further contain a therapeutic ingredient for skin diseases other than the oxidized coenzyme Q and reduced coenzyme Q. As such ingredient, there may be mentioned those drugs which are generally used in the area of dermatological treatment, for example anti-inflammatory agents, immunosuppressives, antibacterial substances, antifungal agents, and disinfectants and, further, such antioxidant substances or skin activating ingredients as mentioned above.

[0030] When the therapeutic composition for skin diseases according to the invention is intended for use in the treatment of atopic dermatitis, it preferably further contains a therapeutic agent for atopic dermatitis other than the oxidized coenzyme Q and reduced coenzyme Q. Such therapeutic agent for atopic dermatitis may be any of those generally used in the treatment of atopic dermatitis, including steroids, more specifically prednisolone valerate acetate, amcinonide, diflucortolone valerate, dexamethasone valerate, clobetasol propionate, diflorasone diacetate, dexamethasone propionate, betamethasone dipropionate, difluprednate, fluocinonide, halcinonide, budesonide, hydrocortisone butyrate propionate, betamethasone valerate, beclomethasone dipropionate, fluocinolone acetonide, triamcinolone acetonide, flumethasone pivalate, hydrocortisone butyrate, clobetasone butyrate, alclometasone dipropionate, dexamethasone, methylprednisolone acetate, prednisolone, and hydrocortisone acetate, and other drugs than steroids, for example tacrolimus, and antihistamines.

[0031] The dermal composition of the present invention can be used as a cosmetic composition or a skin health care composition. Specific uses include, but are not limited to, cleansers, eye creams, eyeshadows, creams, milky lotions, skin lotions, perfumes, face powders, cosmetic oils, paste perfumes, powders, packs, shaving creams, shaving lotions, suntan oils, anti-suntan oils, suntan lotions, anti-suntan lotions, nail creams, nail enamels, bath cosmetics, rouge, mascara, lipsticks, lip creams, eyeliners, deodorants, cologne waters, etc.

[0032] In this case, the above composition may contain one or more of those cosmetic auxiliaries so far used in the conventional cosmetic or skin health care compositions, for example preservatives, bactericides, perfumes, antifoaming agents, colorants, coloring pigments, thickeners, surfactants, emulsifiers, softening agents, moistening agents and/or humectants, fats, oils, waxes and, further, alcohols, polyols, polymers, foam stabilizers, electrolytes, organic solvents, silicone derivatives, and other ingredients.

[0033] The dermal composition of the present invention can be used also as a bath salt or like composition. The bath salt or like composition so referred to herein means a composition to be dissolved in cold or warm water for use thereof at the time of bathing. The bath salt or like composition of the present invention may comprise additive and other ingredients conventionally used in bath salt preparations.

#### BRIEF DESCRIPTION OF THE DRAWING

[0034] Fig. 1 is a graphic representation of the relationship between the concentration of coenzyme Q<sub>10</sub> in skin and the content of reduced coenzyme Q<sub>10</sub> in sample. The vertical axis denotes the total concentration of coenzyme Q<sub>10</sub> in skin, and the horizontal axis denotes the content of reduced coenzyme Q<sub>10</sub> in coenzyme Q<sub>10</sub> in the sample applied. Each bar represents the mean  $\pm$  standard deviation (n = 4 or 5).

#### BEST MODES FOR CARRYING OUT THE INVENTION

[0035] The following examples and preparation examples illustrate the present invention in more detail. They are, however, by no means limitative of the scope of the present invention.

##### (Example 1)

##### (1) Preparation of test sample 1

[0036] Reduced coenzyme Q<sub>10</sub> (0.1 g; containing about 5% of oxidized coenzyme Q<sub>10</sub>) was melted on a water bath at 50°C. Thereto was added polyethylene glycol 1500 (PEG 1500) melted in the same manner to make a total amount of 10 ml. This was made homogeneous by melting and mixing at 50°C and then allowed to solidify at room temperature to give an ointment-like composition.

##### (2) Preparation of comparative sample 1

[0037] Oxidized coenzyme Q<sub>10</sub> (0.1 g) was melted on a water bath at 50°C. Thereto was added PEG 1500 to make a total amount of 10 ml. This was made homogeneous by melting and mixing at 50°C and then allowed to solidify at room temperature to give an ointment-like composition.

## (3) Percutaneous absorption test

**[0038]** The test sample 1 and comparative sample 1 were used as test substances. The test was carried out using male hairless rats (weighing 250 to 300 g) fed under well-fed conditions. A 0.1-g portion of the test sample 1, comparative sample 1, or PEG 1500 as a control was applied to an area of 3 cm square on the back of each hairless rat lightly anesthetized with ether. Three hours, 8 hours or 24 hours after application, the rat was sacrificed by euthanasia, the applied area was washed thoroughly, and a skin sample was taken. The skin sample was homogenized and extracted with propanol, the extract was concentrated using a solid phase column, and the amount of coenzyme Q<sub>10</sub> in the skin was determined by high-performance liquid chromatography. The total amount of coenzyme Q<sub>10</sub> in each skin sample is shown in Table 1. The numerical value shows the mean value  $\pm$  standard deviation.

Table 1

	Coenzyme Q <sub>10</sub> concentration in skin (μg/g)		
	3hr	8hr	24hr
Control (PEG 1500)	1.51 $\pm$ 0.38	1.35 $\pm$ 0.39	1.62 $\pm$ 0.50
Oxidized coenzyme Q <sub>10</sub>	8.32 $\pm$ 1.35 (100)	7.87 $\pm$ 1.75 (100)	7.63 $\pm$ 2.69 (100)
Reduced coenzyme Q <sub>10</sub> <sup>#1</sup>	13.72 $\pm$ 0.70 (1 65 <sup>***</sup> )	17.96 $\pm$ 4.85 (228 <sup>*</sup> )	15.68 $\pm$ 3.95 (206 <sup>*</sup> )
Mean $\pm$ SD, n = 3 to 8.			

\*: p &lt; 0.05,

\*\*\*: p &lt; 0.001, in one-tailed Student's t-test.

#1: Containing about 5% of oxidized coenzyme Q<sub>10</sub>.

**[0039]** As shown above, it was revealed that the coenzyme Q<sub>10</sub> containing 95% of reduced coenzyme Q<sub>10</sub> is very effective in increasing the amount of coenzyme Q<sub>10</sub> in skin as compared with 100% oxidized coenzyme Q<sub>10</sub>.

**[0040]** Each of the skin samples mentioned above was homogenized and extracted with hexane, the extract was evaporated to dryness and dissolved in ethanol, and the proportion of reduced coenzyme Q<sub>10</sub> in skin was determined by high-performance liquid chromatography with an electrochemical detector. The amounts of reduced coenzyme Q<sub>10</sub> in skin thus found are shown in Table 2. Each numerical value means the mean  $\pm$  standard deviation.

Table 2

	Reduced coenzyme Q <sub>10</sub> concentration in skin (μg/g)		
	3hr	8hr	24hr
Control (PEG 1500)	1.11 $\pm$ 0.26	0.84 $\pm$ 0.23	1.13 $\pm$ 0.39
Oxidized coenzyme Q <sub>10</sub>	3.02 $\pm$ 1.22 (100)	4.99 $\pm$ 2.12 (100)	5.44 $\pm$ 2.36 (100)
Reduced coenzyme Q <sub>10</sub> <sup>#1</sup>	12.55 $\pm$ 0.51 (414 <sup>***</sup> )	15.84 $\pm$ 4.56 (317 <sup>**</sup> )	12.99 $\pm$ 4.81 (239 <sup>*</sup> )
Mean $\pm$ SD, n = 3 to 8.			

\*: p &lt; 0.05,

\*\*: p &lt; 0.01,

\*\*\*: p &lt; 0.001, in one-tailed Student's t-test.

#1: Containing about 5% of oxidized coenzyme Q<sub>10</sub>.

**[0041]** As shown above, it was revealed that the coenzyme Q<sub>10</sub> containing 95% of reduced coenzyme Q<sub>10</sub> is very effective in increasing the amount of reduced coenzyme Q<sub>10</sub> in skin as compared with 100% oxidized coenzyme Q<sub>10</sub>. Although the amount of reduced coenzyme Q<sub>10</sub> in skin is gradually increased by the reduction of oxidized coenzyme Q<sub>10</sub> in the treated skin, the rate thereof is not very rapid. Even after 24 hours after application of oxidized coenzyme Q<sub>10</sub>, the amount of reduced coenzyme Q<sub>10</sub> in skin is only half or less as compared with the level 3 hours after application of reduced coenzyme Q<sub>10</sub>.

(Example 2)

(1) Preparation of test sample 2

- 5 [0042] The sample was prepared in the same manner as described above in Example 1 for test sample 1 except that a mixture of oxidized coenzyme Q<sub>10</sub> and reduced coenzyme Q<sub>10</sub> in a mixing ratio of 80:20 by weight was used.

(2) Preparation of test sample 3

- 10 [0043] The sample was prepared in the same manner as described above in Example 1 for test sample 1 except that a mixture of oxidized coenzyme Q<sub>10</sub> and reduced coenzyme Q<sub>10</sub> in a mixing ratio of 60:40 by weight was used.

(3) Preparation of test sample 4

- 15 [0044] The sample was prepared in the same manner as described above in Example 1 for test sample 1 except that a mixture of oxidized coenzyme Q<sub>10</sub> and reduced coenzyme Q<sub>10</sub> in a mixing ratio of 40:60 by weight was used.

(4) Preparation of test sample 5

- 20 [0045] The sample was prepared in the same manner as described above in Example 1 for test sample 1 except that a mixture of oxidized coenzyme Q<sub>10</sub> and reduced coenzyme Q<sub>10</sub> in a mixing ratio of 20:80 by weight was used.

(5) Percutaneous absorption test

- 25 [0046] The test was carried out in the same manner as in Example 1 using the test samples 2, 3, 4 and 5 as well as the comparative sample 1 as test samples.

- [0047] The results of the test are shown in Fig. 1. In Fig. 1, the vertical axis denotes the total amount of coenzyme Q<sub>10</sub> and the amount of reduced coenzyme Q<sub>10</sub> in skin at 3 hours after application, and the horizontal axis denotes the content (% by weight) of reduced coenzyme Q<sub>10</sub> relative to the total amount of coenzyme Q<sub>10</sub> in the sample applied.  
30 Each bar indicates the mean value.

- [0048] As is evident from Fig. 1, the composition in which the proportion of reduced coenzyme Q<sub>10</sub> was 20% by weight gave a significantly increased concentration of reduced coenzyme Q<sub>10</sub> in skin as compared with the composition comprising oxidized coenzyme Q<sub>10</sub> alone. Further, with the composition containing reduced coenzyme Q<sub>10</sub> in a proportion of 40% by weight, a still higher concentration was observed as compared with the composition containing reduced coenzyme Q<sub>10</sub> in a proportion of 20% by weight. From these results, it was revealed that when it contains not  
35 less than 20% by weight of reduced coenzyme Q<sub>10</sub>, the composition of the present invention can undoubtedly increase the amount of reduced coenzyme Q<sub>10</sub> in skin as compared with the composition containing oxidized coenzyme Q<sub>10</sub> alone or the composition containing less than 20% by weight of reduced coenzyme Q<sub>10</sub> relative to the total amount of coenzyme Q<sub>10</sub>.

(Example 3)

Therapeutic effect in atopic dermatitis model mice (NC mice) - 1

- 45 [0049] The method of Hirasawa et al. (Oyo Yakuri (Applied Pharmacology), Vol. 59, No. 6, pp. 123-134, 2000) was used for the evaluation. Ointments containing oxidized coenzyme Q<sub>10</sub> and ointments containing reduced coenzyme Q<sub>10</sub> (containing 5% of oxidized coenzyme Q<sub>10</sub> in coenzyme Q<sub>10</sub>) were evaluated for therapeutic effect in atopic dermatitis model mice (NC mice). Dermatitis was induced in each group of 7 NC mice by sensitizing (once a week) using a hapten. On the occasion of the third sensitization, the treatment with each test compound was started. The coenzyme  
50 Q<sub>10</sub>-containing ointment (1%) was applied at a dose of 0.1 g every day, while the positive control prednisolone ointment was applied once every other day. In the group in which the prednisolone ointment and the coenzyme Q<sub>10</sub> ointment were used combinedly, the ointments were applied alternately. The therapeutic effect was evaluated on a scoring scale of 0 to 3 (0: no symptom, 1: slight, 2: medium, 3: severe) for the 5 items: 1 - pruritus, 2 - rubefaction, bleeding, 3 - edema, 4 - abrasion, tissue deficit, 5 - crusting, dryness. The differences between the dermatitis scores at the start of  
55 the test and those on day 15 after the start of application are shown in Table 3. Each data indicates the mean ± standard deviation.



Table 3

Test group	Increase in dermatitis score
Control group	4.4 ± 1.18 (100)
1% Oxidized coenzyme Q <sub>10</sub> ointment	3.3 ± 2.14 (75)
1% Reduced coenzyme Q <sub>10</sub> ointment*	3.1 ± 2.04 (70)
Prednisolone ointment (P)	2.1 ± 1.35 (48)
Prednisolone ointment (P)	2.1 ± 1.35 (100)
P + 1% oxidized coenzyme Q <sub>10</sub> ointment	1.1 ± 1.07 (52)
P + 1% reduced coenzyme Q <sub>10</sub> ointment*	-1.3 ± 1.98 (-)
Mean ± SD, n = 7	

\* Total coenzyme Q<sub>10</sub> contained about 5% of oxidized coenzyme Q<sub>10</sub>.

[0050] A greater score value indicates a higher level of aggravation of dermatitis during testing. In the oxidized, and reduced coenzyme Q<sub>10</sub> ointment groups, the ointments showed an obvious aggravation preventing effect, like in the positive control prednisolone ointment, as compared with the control group. In the group of combined use with prednisolone, a more powerful therapeutic effect was shown as compared with the group of single use of prednisolone, and the reduced coenzyme Q<sub>10</sub> ointment, in particular, gave a score lower than the score at the start of testing, indicating its dermatitis healing ability. It has so far been quite unknown in the art that ointments containing a coenzyme Q as its main active ingredient is actually effective against atopic dermatitis in the manner mentioned above. Furthermore, it has never been anticipated that when used combinedly with a steroid, a coenzyme Q can show such a more potent effect.

(Example 4)

Therapeutic effect in atopic dermatitis model mice (NC mice) - 2

[0051] The effect of the single use of a high concentration coenzyme Q<sub>10</sub> ointment (10%) and the effect of the combined use of Protopic ointment (tacrolimus preparation), a therapeutic agent for atopic dermatitis, and a low concentration coenzyme Q<sub>10</sub> ointment (1%) were examined by carrying out the same test as in Example 3. In the single use evaluation group, the test ointment was applied every day and, in the combined use evaluation group, Protopic ointment was applied at a dose of 0.1 g once a week and 0.1 g of the low concentration coenzyme Q<sub>10</sub> ointment on the remaining 6 days per week. In a control group, Protopic ointment was applied singly 6 times a week. In a positive control group, a prednisolone ointment was applied every other day. The results obtained on the 15th day after commencement of application are shown in Table 4. Each value indicates the mean ± standard deviation.

Table 4

Test group	Increase in dermatitis score
Control group	4.1 ± 0.90 (100)
10% Oxidized coenzyme Q <sub>10</sub> ointment	4.0 ± 1.53 (98)
10% Reduced coenzyme Q <sub>10</sub> ointment*	2.9 ± 1.21 (71)
Prednisolone ointment (P)	2.7 ± 2.14 (66)
Protopic ointment (P)	5.4 ± 1.90 (100)
P + 1 % oxidized coenzyme Q <sub>10</sub> ointment	3.7 ± 1.80 (69)
P + 1 % reduced coenzyme Q <sub>10</sub> ointment*	3.0 ± 1.73 (56)
Mean ± SD, n = 7	

\* Total coenzyme Q<sub>10</sub> contained about 5% of oxidized coenzyme Q<sub>10</sub>.

[0052] The high-concentration reduced coenzyme Q<sub>10</sub> ointment was roughly comparable in therapeutic effect to the positive control prednisolone ointment, indicating that it can show a potent therapeutic effect even when used singly.

On the other hand, Protopic ointment in the single use group showed no efficacy probably due to the small number of applications. However, when Protopic ointment was used in combination with the low concentration coenzyme Q<sub>10</sub> ointment, a distinct synergistic effect was shown and aggravation was suppressed. That the coenzyme Q<sub>10</sub> ointments used combinedly with tacrolimus also showed a synergistic effect like in the combined use with the steroid preparation indicates that the synergistic effect of the coenzyme Q<sub>10</sub> ointment on atopic dermatitis is not specific to the steroid preparation.

(Example 5)

#### 10 Incised wound healing test in rats

[0053] SD rats (male, 12-week-old) were clipped of hairs and divided into groups of 10 animals to make the mean body weights of the groups roughly the same, and subjected to the test. Each animal was given an incision wound along the median line under diethyl ether anesthesia. The incision wound was stapled at three sites using Michel's clips, and a 1% oxidized coenzyme Q<sub>10</sub> ointment or a 1% reduced coenzyme Q<sub>10</sub> ointment was applied at a dose of 0.2 g/day for 4 days. Two control groups, namely a nontreated group and an ointment base group treated with the same dose of the ointment base, were used. Three days after incision, the Michel's clips were removed and, four days after incision, each animal was euthanized by overanesthesia with diethyl ether, the skin around the incision was peeled off, and skin sections were prepared. The skin sections were measured for tension on a tensile tester.

[0054] As a result, it was noted that oxidized coenzyme Q<sub>10</sub> and reduced coenzyme Q<sub>10</sub> have a skin repair promoting effect.

(Example 6)

#### 25 Oxidation stability evaluation of reduced coenzyme Q<sub>10</sub> in ointment

[0055] Reduced coenzyme Q<sub>10</sub>-containing ointments were evaluated for oxidation stability. The ointment bases used were PEG 1500, a hydrophilic ointment, an absorptive ointment, and a simple ointment. The PEG 1500 used was a product of Wako Pure Chemical Industries, and the hydrophilic ointment, absorptive ointment and simple ointment used were respectively the products according to the Japanese Pharmacopoeia. Using the respective bases and reduced coenzyme Q<sub>10</sub>, ointments were prepared in the same manner as in Example 1. The thus-prepared reduced coenzyme Q<sub>10</sub> ointments were stored at 23°C for 2 weeks either in air or in a vessel purged with nitrogen, and the proportion of the reduced form of coenzyme Q<sub>10</sub> in each ointment was determined by HPLC. The results thus obtained are shown in Table 5.

Table 5

Base	Concentration (%) <sup>*1</sup>	Proportion of reduced coenzyme Q <sub>10</sub> (%) <sup>*2</sup>		
		4° C in air	23° C in air	23° C in nitrogen
PEG1500	1	87.5	56.4	62.3
PEG1500	10	92.5	94.4	93.6
Hydrophilic ointment	1	-	75.1	79.3
Absorptive ointment	1	-	29.8	5.3
Simple ointment	1	-	83.9	83.6
Mean, n = 2				

<sup>\*1</sup> Concentration of coenzyme Q<sub>10</sub> in ointment

<sup>\*2</sup> Proportion of reduced coenzyme Q<sub>10</sub> in total coenzyme Q<sub>10</sub> in ointment after 2 weeks of storage under respective conditions.

- Not tested.

[0056] In the reduced coenzyme Q<sub>10</sub> ointments prepared by using simple ointment and hydrophilic ointment, respectively, as bases, about 80% of coenzyme Q<sub>10</sub> retained the reduced form after the 2 weeks of storage whereas, in the PEG 1500-based and absorptive ointment-based ointments, only 60% and 30%, respectively, of the reduced form remained. As regards the oxidation stability of reduced coenzyme Q<sub>10</sub> in the ointments, the substitution of the storage vessel atmosphere with nitrogen showed no protective effect. When the PEG 1500-based ointment was stored at 4°C in a refrigerator, the enzyme stability was assured for 2 weeks. Evaluation of the dependency on the concentration of reduced coenzyme Q<sub>10</sub> in ointment revealed that the 10% ointment is higher in stability than the 1% preparation, namely

the higher the concentration is, the more stable the preparation is.

(Preparation Example 1)

- 5 **[0057]** A coenzyme Q<sub>10</sub>-containing hydrophilic ointment was prepared by a conventional method according to the following formulation.

Hydrophilic ointment	99.000% by weight
coenzyme Q <sub>10</sub>	1.000% by weight

(Preparation Example 2)

- 15 **[0058]** A coenzyme Q<sub>10</sub>-containing W/O cream was prepared by a conventional method according to the following formulation.

Glycerol sorbitan fatty acid ester	6.000 % by weight
Microcrystalline wax	1.000% by weight
Olive oil	3.000% by weight
Liquid paraffin	19.000% by weight
Magnesium stearate	1.000% by weight
Propylene glycol	3.700% by weight
Magnesium sulfate (MgSO <sub>4</sub> ·7H <sub>2</sub> O)	0.700% by weight
Coenzyme Q <sub>10</sub>	1.000% by weight
Dehydrated salt to make	100.000% by weight

(Preparation Example 3)

- 30 **[0059]** A coenzyme Q<sub>10</sub>-containing W/O emulsion was prepared by a conventional method according to the following formulation.

Polyoxyethylene glycerol sorbitan fatty acid ester	3.600% by weight
Polyoxyethylene fatty acid ester	1.400% by weight
Cetearyl alcohol	2.000% by weight
Mineral oil, GP 9	20.000% by weight
Paraben mixture	q.v.
Magnesium sulfate (MgSO <sub>4</sub> ·7H <sub>2</sub> O)	0.700% by weight
Coenzyme Q <sub>10</sub>	1.000% by weight
Calcium chloride (CaCl <sub>2</sub> )	0.85% by weight
Dehydrated salt to make	100.000% by weight

(Preparation Example 4)

- 45 **[0060]** A coenzyme Q<sub>10</sub>-containing W/O lotion was prepared by a conventional method according to the following formulation.


Glycerol sorbitan fatty acid ester	1.300% by weight
Polyoxyethylene fatty acid ester	3.700% by weight
Neutral oil	6.000% by weight
Liquid paraffin, GP 9	14.000% by weight
Propylene glycol	3.800% by weight
Magnesium sulfate (MgSO <sub>4</sub> ·7H <sub>2</sub> O)	0.700% by weight
Ribonic acid	1.500% by weight
Coenzyme Q <sub>10</sub>	1.000% by weight
Desalted water to make	100.000% by weight

## INDUSTRIAL APPLICABILITY


[0061] The composition of the present invention; which has the above constitution, is excellent in percutaneous absorption of coenzyme Q<sub>10</sub> and highly effective in the treatment of skin diseases, such as atopic dermatitis, and in skin health care.

## Claims

1. A composition for dermal application  
which comprises, as an active ingredient, an oxidized coenzyme Q represented by the formula (1):



in which n represents an integer of 1 to 12,  
and/or a reduced coenzyme Q represented by the formula (2):




In which n represents an Integer of 1 to 12,  
the total content of the oxidized coenzyme Q and reduced coenzyme Q being 0.01 to 99% by weight relative to the whole amount of the composition.

2. The composition for dermal application according to Claim 1,  
wherein the proportion of the reduced coenzyme Q relative to the total amount of the oxidized coenzyme Q represented by the formula (1) and the reduced coenzyme Q represented by the formula (2) is not less than 20% by weight.
3. The composition for dermal application according to Claim 2,  
wherein the proportion of the reduced coenzyme Q relative to the total amount of the oxidized coenzyme Q represented by the formula (1) and the reduced coenzyme Q represented by the formula (2) is not less than 40% by weight.
4. The composition for dermal application according to any of Claims 1 to 3,  
wherein the proportion of the reduced coenzyme Q relative to the total amount of the oxidized coenzyme Q represented by the formula (1) and the reduced coenzyme Q represented by the formula (2) is not more than 95% by weight.

5. The composition for dermal application according to Claim 1,  
which does not contain any of the reduced coenzymes Q represented by the formula (2) but contains an oxidized coenzyme Q represented by the formula (1).
- 5 6. The composition for dermal application according to any of Claims 1 to 5,  
wherein the oxidized coenzyme Q represented by the general formula (1) is oxidized coenzyme Q<sub>10</sub> and the reduced coenzyme Q represented by the general formula (2) is reduced coenzyme Q<sub>10</sub>.
7. The composition for dermal application according to any of Claims 1 to 6,  
10 which is to be applied to a human.
8. The composition for dermal application according to any of Claims 1 to 6,  
which is to be applied to pets, a domestic animal and/or a bird.
- 15 9. The composition for dermal application according to Claim 8,  
which is to be applied to a dog and/or a cat.
10. A therapeutic composition for skin diseases  
which comprises the composition for dermal application according to any of Claims 1 to 9.
- 20 11. The therapeutic composition for skin diseases according to Claim 10,  
which is to be used for the treatment of at least one skin disease selected from the group consisting of atopic dermatitis, decubitus, wounds, burns, psoriasis, eruptions, contact dermatitis, seborrheic dermatitis, lichen simplex chronicus Vidal, nummular eczema, housewives' eczema, solar dermatitis, pruritus cutaneus, prurigo, drug eruption,  
25 lichen planus, pityriasis rubra pilaris Devergie, pityriasis rosea Gibert, erythema, erythrodermia, wounds, athlete's foot, and skin ulcer.
12. The therapeutic composition for skin diseases according to Claim 10 or 11,  
which further comprises a therapeutic ingredient for skin diseases other than the oxidized coenzyme Q represented by the formula (1) and other than the reduced coenzyme Q represented by the formula (2).
- 30 13. The therapeutic composition for skin diseases according to Claim 12,  
wherein the therapeutic ingredient for skin diseases other than the oxidized coenzyme Q represented by the formula (1) and other than the reduced coenzyme Q represented by the formula (2) is a therapeutic agent for atopic dermatitis other than the oxidized coenzyme Q represented by the formula (1) and other than the reduced coenzyme Q represented by the formula (2).
- 35 14. The therapeutic composition for skin diseases according to Claim 13,  
wherein the therapeutic agent for atopic dermatitis other than the oxidized coenzyme Q represented by the formula (1) and other than the reduced coenzyme Q represented by the formula (2) is a steroid or tacrolimus.
- 40 15. A cosmetic composition  
which comprises the composition for dermal application according to any of Claims 1 to 9.
- 45 16. A skin health care composition  
which comprises the composition for dermal application according to any of Claims 1 to 9.
17. A bath salt composition  
which comprises the composition for dermal application according to any of Claims 1 to 9.
- 50 18. A method for the treatment of skin diseases  
which comprises applying, to a patient suffering from a skin disease, the therapeutic composition for skin diseases according to any of Claims 10 to 14.
- 55 19. A method for the treatment of skin diseases  
which comprises applying, to a patient suffering from a skin disease, a therapeutic agent for skin diseases other than the oxidized coenzyme Q represented by the formula (1) and other than the reduced coenzyme Q represented by the formula (2) in parallel with a therapeutic composition for skin diseases according to any of Claims 10 to 14.

Fig. 1



\* :  $p < 0.05$ , \*\* :  $p < 0.01$ , \*\*\* :  $p < 0.001$ ,  
in one-tailed Student's t-test

## INTERNATIONAL SEARCH REPORT

International application No.

PCT/JP01/03863

A. CLASSIFICATION OF SUBJECT MATTER  
Int.Cl<sup>7</sup> A61K31/05, 31/122, 9/06, 9/107, 7/00, 7/40, A61P37/08, 17/00, 17/02, 17/04, 17/06, 17/08

According to International Patent Classification (IPC) or to both national classification and IPC

## B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

Int.Cl<sup>7</sup> A61K31/05, 31/122, 9/06, 9/107, 7/00, 7/40, A61P37/08, 17/00, 17/02, 17/04, 17/06, 17/08

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practicable, search terms used)  
CAPLUS (STN), MEDLINE (STN), EMBASE (STN)

## C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	US 6048886 A (NEIGUT Stanley), 11 April, 2000 (11.04.00), especially, Column 12, EXAMPLE 11, (Family: none)	1-17
X	JP 2-059519 A (EISAI CO., LTD.), 28 February, 1998 (28.02.98) (Family: none) & Database CAPLUS on STN, AMERICAN CHEMICAL SOCIETY (ACS), (Columbus, OH, USA), DN.113:46317	1-17
X	JP 61-27914 A (Shiseido Company, Limited), 07 February, 1986 (07.02.86) (Family: none) & Database CAPLUS on STN, AMERICAN CHEMICAL SOCIETY (ACS), (Columbus, OH, USA), DN.104:192915	1-17
X	JP 59-13719 A (Shiseido Company, Limited), 24 January, 1984 (24.01.84) (Family: none) & Database CAPLUS on STN, AMERICAN CHEMICAL SOCIETY (ACS), (Columbus, OH, USA), DN.100:168237	1-17
X	JP 58-180410 A (Shiseido Company, Limited), 21 October, 1983 (21.10.83) (Family: none) & Database CAPLUS on STN, AMERICAN CHEMICAL SOCIETY	1-17

☒ Further documents are listed in the continuation of Box C. ☐ See patent family annex.

\* Special categories of cited documents:  
"A" document defining the general state of the art which is not considered to be of particular relevance  
"E" earlier document but published on or after the international filing date  
"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)  
"O" document referring to an oral disclosure, use, exhibition or other means  
"P" document published prior to the international filing date but later than the priority date claimed

"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention  
"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone  
"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art  
"&" document member of the same patent family

Date of the actual completion of the international search  
02 August, 2001 (02.08.01)

Date of mailing of the international search report  
14 August, 2001 (14.08.01)

Name and mailing address of the ISA/  
Japanese Patent Office

Authorized officer

Facsimile No.

Telephone No.

Form PCT/ISA/210 (second sheet) (July 1992)

## INTERNATIONAL SEARCH REPORT

International application No.

PCT/JP01/03863

## C (Continuation). DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
Y	(ACS) , (Columbus, OH, USA) , DN.100:39458 WO 95/05852 A1 (BEIERSDORF A. -G.) , 02 March, 1995 (02.03.95) , & EP 721347 A1 & JP 9-501925 A	1-17

Form PCT/ISA/210 (continuation of second sheet) (July 1992)



## INTERNATIONAL SEARCH REPORT

International application No.

PCT/JP01/03863

**Box I Observations where certain claims were found unsearchable (Continuation of Item 1 of first sheet)**

This international search report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. ☒ Claims Nos.: 18,19  
because they relate to subject matter not required to be searched by this Authority, namely:  
Claims 18 and 19 pertain to methods for treatment of the human body by therapy and thus relate to a subject matter which this International Searching Authority is not required, under the provisions of Article 17(2)(a)(i) of the PCT and Rule 39(iv) of the Regulations under the PCT, to search.
2. ☐ Claims Nos.:  
because they relate to parts of the international application that do not comply with the prescribed requirements to such an extent that no meaningful international search can be carried out, specifically:
3. ☐ Claims Nos.:  
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

**Box II Observations where unity of invention is lacking (Continuation of Item 2 of first sheet)**

This International Searching Authority found multiple inventions in this international application, as follows:

1. ☐ As all required additional search fees were timely paid by the applicant, this international search report covers all searchable claims.
2. ☐ As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.
3. ☐ As only some of the required additional search fees were timely paid by the applicant, this international search report covers only those claims for which fees were paid, specifically claims Nos.:
4. ☐ No required additional search fees were timely paid by the applicant. Consequently, this international search report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

Remark on Protest ☐ The additional search fees were accompanied by the applicant's protest.  
☐ No protest accompanied the payment of additional search fees.

Form PCT/ISA/210 (continuation of first sheet (1)) (July 1992)